US7081514B2
(en)
*
|
1998-09-01 |
2006-07-25 |
Genentech, Inc. |
PRO1347 polypeptides
|
DE19951360A1
(de)
*
|
1999-10-26 |
2001-05-03 |
Aventis Pharma Gmbh |
Substituierte Indole
|
JP2001131151A
(ja)
*
|
1999-11-02 |
2001-05-15 |
Shionogi & Co Ltd |
オレフィン誘導体の新規用途
|
NZ525474A
(en)
|
2000-10-26 |
2005-10-28 |
Tularik Inc |
Antiinflammation agents
|
DE10115073A1
(de)
*
|
2001-03-27 |
2002-10-10 |
Procorde Gmbh |
Verwendung von Inhibitoren von IKK-ß und Verfahren zum Auffinden solcher Inhibitoren
|
WO2002079192A1
(en)
*
|
2001-03-28 |
2002-10-10 |
Bristol-Myers Squibb Company |
Novel tyrosine kinase inhibitors
|
US7405235B2
(en)
*
|
2001-05-04 |
2008-07-29 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
WO2004001058A2
(en)
*
|
2001-05-04 |
2003-12-31 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
AU2002316765B2
(en)
*
|
2001-06-13 |
2007-04-05 |
Bhp Billiton Sa Limited |
Solvent extraction mixture comprising substituted imidazole or benzimidazole for the separation of groups of base metals
|
WO2002101101A2
(en)
*
|
2001-06-13 |
2002-12-19 |
Billiton Sa Limited |
Solvent extraction mixture comprising substituted imidazole or benzimidazole for the purification of base metals
|
US8124625B2
(en)
|
2001-09-14 |
2012-02-28 |
Shionogi & Co., Ltd. |
Method of enhancing the expression of apolipoprotein AI using olefin derivatives
|
US6897208B2
(en)
*
|
2001-10-26 |
2005-05-24 |
Aventis Pharmaceuticals Inc. |
Benzimidazoles
|
FR2831536A1
(fr)
*
|
2001-10-26 |
2003-05-02 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
|
IL161576A0
(en)
*
|
2001-10-26 |
2004-09-27 |
Aventis Pharma Inc |
Benzimidazoles and analogues and their use as protein kinases inhibitors
|
FR2831537B1
(fr)
*
|
2001-10-26 |
2008-02-29 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
|
US7176314B2
(en)
|
2001-12-05 |
2007-02-13 |
Amgen, Inc. |
Inflammation modulators
|
EP1474425B9
(en)
|
2002-01-07 |
2008-07-02 |
Eisai Co., Ltd. |
Deazapurines and uses thereof
|
KR20040094677A
(ko)
|
2002-01-29 |
2004-11-10 |
와이어쓰 |
코넥신 헤미채널 조절을 위한 조성물 및 방법
|
US7199990B2
(en)
|
2002-01-30 |
2007-04-03 |
Siemens Aktiengesellschaft |
Device for short-circuiting two electric lines for reducing a voltage differential
|
US20040034037A1
(en)
*
|
2002-02-06 |
2004-02-19 |
Harbeson Scott L. |
Heteroaryl compounds useful as inhibitors of GSK-3
|
US7528161B2
(en)
*
|
2002-05-31 |
2009-05-05 |
Michigan State University |
NF-kappaB inhibitors and uses thereof
|
US20080114015A1
(en)
*
|
2002-05-31 |
2008-05-15 |
Board Of Trustees Of Michigan State University |
NF-kB inhibitors and uses thereof
|
US6974870B2
(en)
|
2002-06-06 |
2005-12-13 |
Boehringer Ingelheim Phamaceuticals, Inc. |
Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
|
AU2003237330A1
(en)
|
2002-06-06 |
2003-12-22 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
|
CN100345593C
(zh)
*
|
2002-08-06 |
2007-10-31 |
东丽株式会社 |
用于制备肾脏疾病的治疗或预防药物中的用途
|
CN1703395A
(zh)
*
|
2002-08-09 |
2005-11-30 |
特兰斯泰克制药公司 |
芳基和杂芳基化合物以及调节凝血的方法
|
DE10237723A1
(de)
*
|
2002-08-17 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
|
DE10237722A1
(de)
*
|
2002-08-17 |
2004-08-19 |
Aventis Pharma Deutschland Gmbh |
Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
|
US7462638B2
(en)
*
|
2002-08-17 |
2008-12-09 |
Sanofi-Aventis Deutschland Gmbh |
Use of IκB-kinase inhibitors in pain therapy
|
DE10238002A1
(de)
*
|
2002-08-20 |
2004-03-04 |
Merck Patent Gmbh |
Benzimidazolderivate
|
KR20050057404A
(ko)
*
|
2002-09-17 |
2005-06-16 |
워너-램버트 캄파니 엘엘씨 |
정신분열증 치료용 헤테로환 치환된 피페라진
|
WO2004041285A1
(en)
|
2002-10-31 |
2004-05-21 |
Amgen Inc. |
Antiinflammation agents
|
CA2504044A1
(en)
*
|
2002-11-01 |
2004-05-21 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
US7640843B2
(en)
*
|
2003-01-24 |
2010-01-05 |
Kraft Foods R & D, Inc. |
Cartridge and method for the preparation of beverages
|
US20050256132A1
(en)
*
|
2003-04-30 |
2005-11-17 |
Wyeth |
Use of ER selective NF-kB inhibitors for the treatment of sepsis
|
US20050004164A1
(en)
*
|
2003-04-30 |
2005-01-06 |
Caggiano Thomas J. |
2-Cyanopropanoic acid amide and ester derivatives and methods of their use
|
WO2004101745A2
(en)
*
|
2003-05-08 |
2004-11-25 |
Beth Israel Deaconess Medical Center, Inc. |
NOVEL REGULATORY MECHANISMS OF NF-kappaB
|
TWI372050B
(en)
*
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
US7459472B2
(en)
*
|
2003-08-08 |
2008-12-02 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions, and methods of use
|
AU2004263508A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions, and methods of use
|
US7208601B2
(en)
*
|
2003-08-08 |
2007-04-24 |
Mjalli Adnan M M |
Aryl and heteroaryl compounds, compositions, and methods of use
|
TWI352705B
(en)
*
|
2003-09-08 |
2011-11-21 |
Aventis Pharma Inc |
Thienopyrazoles
|
AU2004283313A1
(en)
*
|
2003-10-24 |
2005-05-06 |
Exelixis, Inc. |
TAO kinase modulators and methods of use
|
RU2006123704A
(ru)
*
|
2003-12-05 |
2008-01-20 |
Берингер Ингельхайм Фармасьютиклз, Инк. (Us) |
ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ АМИДО 3-АМИНОТИЕНО[2, 3-b]ПИРИДИН-2-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ IKK
|
US20060160799A1
(en)
|
2004-04-23 |
2006-07-20 |
Alekshun Michael N |
Transcription factor modulating compounds and methods of use thereof
|
US7425580B2
(en)
|
2004-05-19 |
2008-09-16 |
Wyeth |
(Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
|
PE20060373A1
(es)
|
2004-06-24 |
2006-04-29 |
Smithkline Beecham Corp |
Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
|
JP5507049B2
(ja)
*
|
2004-12-30 |
2014-05-28 |
アステックス、セラピューティックス、リミテッド |
医薬品
|
WO2006070192A1
(en)
*
|
2004-12-30 |
2006-07-06 |
Astex Therapeutics Limited |
Thiazole and isothiazole derivatives that modulate the acivity of cdk, gsk and aurora kynases
|
JP5066514B2
(ja)
*
|
2005-03-14 |
2012-11-07 |
ハイ ポイント ファーマシューティカルズ,エルエルシー |
ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法
|
GEP20115138B
(en)
*
|
2005-03-30 |
2011-01-10 |
Takeda Pharmaceuticals Co |
Benzimidazole derivative and use as angiotensin ii antagonist
|
TWI370820B
(en)
*
|
2005-04-27 |
2012-08-21 |
Takeda Pharmaceutical |
Fused heterocyclic compounds
|
WO2007005534A2
(en)
|
2005-06-30 |
2007-01-11 |
Smithkline Beecham Corporation |
Chemical compounds
|
US8063071B2
(en)
|
2007-10-31 |
2011-11-22 |
GlaxoSmithKline, LLC |
Chemical compounds
|
EP2388263A1
(en)
|
2005-08-04 |
2011-11-23 |
Sirtris Pharmaceuticals, Inc. |
Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
|
US7855289B2
(en)
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
US8088928B2
(en)
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
US8093401B2
(en)
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
JP2009001495A
(ja)
*
|
2005-10-13 |
2009-01-08 |
Taisho Pharmaceutical Co Ltd |
2−アリール−ベンゾイミダゾール−5−カルボキサミド誘導体
|
JP5474354B2
(ja)
*
|
2005-12-30 |
2014-04-16 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
CA2637674A1
(en)
*
|
2006-01-19 |
2007-07-26 |
Abbott Laboratories |
2-imino-benzimidazoles
|
EP2004188B1
(en)
*
|
2006-03-31 |
2010-09-01 |
Janssen Pharmaceutica NV |
Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
|
RS51423B
(en)
|
2006-03-31 |
2011-02-28 |
Janssen Pharmaceutica N.V. |
BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
|
JP2009539865A
(ja)
|
2006-06-06 |
2009-11-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
置換3−アミノ−チエノ[2,3−b]ピリジン2−カルボン酸アミド化合物及び製造方法及びそれらの使用
|
WO2008130368A2
(en)
*
|
2006-06-23 |
2008-10-30 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
EP2049119A2
(en)
*
|
2006-06-29 |
2009-04-22 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
|
WO2008001101A2
(en)
*
|
2006-06-29 |
2008-01-03 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
BRPI0715160A2
(pt)
|
2006-08-08 |
2013-06-11 |
Sanofi Aventis |
imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
|
CN101616910A
(zh)
*
|
2006-09-07 |
2009-12-30 |
比奥根艾迪克Ma公司 |
作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物
|
PE20080888A1
(es)
*
|
2006-10-18 |
2008-08-26 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
CA2681813A1
(en)
*
|
2007-03-27 |
2009-01-08 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
CL2008001822A1
(es)
|
2007-06-20 |
2009-03-13 |
Sirtris Pharmaceuticals Inc |
Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
WO2009049238A1
(en)
|
2007-10-11 |
2009-04-16 |
The Regents Of The University Of California |
Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase
|
WO2009079001A1
(en)
|
2007-12-18 |
2009-06-25 |
Janssen Pharmaceutica N.V. |
Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
|
US11969501B2
(en)
|
2008-04-21 |
2024-04-30 |
Dompé Farmaceutici S.P.A. |
Auris formulations for treating otic diseases and conditions
|
KR20130097813A
(ko)
|
2008-04-21 |
2013-09-03 |
오토노미, 인코포레이티드 |
귀 질환 및 병태를 치료하기 위한 귀 조제물
|
WO2009134847A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
US9371311B2
(en)
|
2008-06-30 |
2016-06-21 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyrimidine derivatives
|
JP5758292B2
(ja)
|
2008-07-03 |
2015-08-05 |
サートリス ファーマシューティカルズ, インコーポレイテッド |
サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
BRPI0922435A2
(pt)
|
2008-12-19 |
2018-09-11 |
Sirtris Pharmaceuticals Inc |
"composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
|
JP2012520257A
(ja)
|
2009-03-10 |
2012-09-06 |
グラクソ グループ リミテッド |
Ikk2阻害剤としてのインドール誘導体
|
US20110059962A1
(en)
*
|
2009-04-22 |
2011-03-10 |
Alekshun Michael N |
Transcription factor modulating compounds and methods of use thereof
|
EP2464231A4
(en)
*
|
2009-08-10 |
2013-02-06 |
Samumed Llc |
INDAZOLE AS WNT / B-CATENINE SIGNALING PATHWASHER AND THERAPEUTIC APPLICATIONS THEREOF
|
HUE028259T2
(en)
|
2009-08-10 |
2016-12-28 |
Samumed Llc |
Inhibitors of Wnt signaling signal indazole and their therapeutic use
|
EP2470552B1
(en)
|
2009-08-26 |
2013-11-13 |
Sanofi |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
WO2011045415A2
(en)
*
|
2009-10-15 |
2011-04-21 |
Guerbet |
New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
|
JP5822844B2
(ja)
|
2009-12-21 |
2015-11-24 |
サミュメッド リミテッド ライアビリティ カンパニー |
1H−ピラゾロ[3,4−b]ピリジンおよびその治療的使用
|
EP2536285B1
(en)
|
2010-02-18 |
2018-04-25 |
vTv Therapeutics LLC |
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
|
US8759535B2
(en)
|
2010-02-18 |
2014-06-24 |
High Point Pharmaceuticals, Llc |
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
WO2012120057A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
CA2834680A1
(en)
*
|
2011-04-29 |
2012-11-01 |
Emory University |
Selecting use of proteasome inhibitors based on nf-kb2 sequence
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
IN2014CN02646A
(xx)
|
2011-09-14 |
2015-08-07 |
Samumed Llc |
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
ES2625518T3
(es)
|
2011-11-22 |
2017-07-19 |
The Regents Of The University Of California |
Beta-lactonas disustituidas como inhibidores de amidasa de ácido N-aciletanolamina (NAAA)
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
NZ724837A
(en)
|
2012-05-04 |
2018-05-25 |
Samumed Llc |
1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
MX370487B
(es)
|
2013-01-08 |
2019-12-16 |
Samumed Llc |
Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos.
|
MX2015011688A
(es)
|
2013-03-06 |
2015-12-07 |
Janssen Pharmaceutica Nv |
Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
|
WO2014144836A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
|
WO2014144547A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
|
CN105849087A
(zh)
|
2013-12-27 |
2016-08-10 |
诺华丝国际股份有限公司 |
乙氧基化表面活性剂
|
EP3102576B8
(en)
|
2014-02-03 |
2019-06-19 |
Vitae Pharmaceuticals, LLC |
Dihydropyrrolopyridine inhibitors of ror-gamma
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016089648A1
(en)
|
2014-12-01 |
2016-06-09 |
Vtv Therapeutics Llc |
Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
WO2017023996A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
US10604512B2
(en)
|
2015-08-03 |
2020-03-31 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
WO2017024015A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024003A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017024004A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10195185B2
(en)
|
2015-08-03 |
2019-02-05 |
Samumed, Llc |
3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017024021A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017079759A1
(en)
|
2015-11-06 |
2017-05-11 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
|
MA53943A
(fr)
|
2015-11-20 |
2021-08-25 |
Vitae Pharmaceuticals Llc |
Modulateurs de ror-gamma
|
TW202220968A
(zh)
*
|
2016-01-29 |
2022-06-01 |
美商維它藥物有限責任公司 |
ROR-γ調節劑
|
US10590084B2
(en)
|
2016-03-09 |
2020-03-17 |
Blade Therapeutics, Inc. |
Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
|
HRP20221446T1
(hr)
|
2016-06-01 |
2023-01-06 |
Biosplice Therapeutics, Inc. |
Postupci za pripremu n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida
|
JP7033789B2
(ja)
|
2016-06-29 |
2022-03-11 |
オトノミー,インク. |
トリグリセリド耳用製剤とその使用
|
EP3481835A4
(en)
|
2016-07-05 |
2020-02-26 |
Blade Therapeutics, Inc. |
CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
|
ES2973850T3
(es)
|
2016-09-20 |
2024-06-24 |
Centre Leon Berard |
Derivados del benzoimidazol como agentes anticancerígenos
|
PE20191153A1
(es)
|
2016-09-28 |
2019-09-05 |
Blade Therapeutics Inc |
Moduladores de calpainas y usos terapeuticos de los mismos
|
BR112019008061A2
(pt)
|
2016-10-21 |
2019-09-17 |
Samumed Llc |
métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina
|
JP2019533702A
(ja)
|
2016-11-07 |
2019-11-21 |
サミュメッド リミテッド ライアビリティ カンパニー |
単回用量の調整済み注射用製剤
|
WO2019018975A1
(en)
|
2017-07-24 |
2019-01-31 |
Vitae Pharmaceuticals, Inc. |
INHIBITORS OF ROR GAMMA
|
AU2018307919B2
(en)
|
2017-07-24 |
2022-12-01 |
Vitae Pharmaceuticals, Llc |
Inhibitors of RORϒ
|
US10584306B2
(en)
|
2017-08-11 |
2020-03-10 |
Board Of Regents Of The University Of Oklahoma |
Surfactant microemulsions
|
US11447482B1
(en)
|
2019-02-14 |
2022-09-20 |
KUDA Therapeutics, Inc. |
Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis
|